Home > Publications Database > Integrity of neural extracellular matrix is required for microglia-mediated synaptic remodeling. > print

001     271336
005     20240901004630.0
024 7 _ |a 10.1002/glia.24588
|2 doi
024 7 _ |a pmid:38946065
|2 pmid
024 7 _ |a 0894-1491
|2 ISSN
024 7 _ |a 1098-1136
|2 ISSN
024 7 _ |a altmetric:164963008
|2 altmetric
037 _ _ |a DZNE-2024-01038
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Cangalaya, Carla
|0 P:(DE-2719)9001455
|b 0
|e First author
|u dzne
245 _ _ |a Integrity of neural extracellular matrix is required for microglia-mediated synaptic remodeling.
260 _ _ |a Bognor Regis [u.a.]
|c 2024
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1724754588_30327
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Microglia continuously remodel synapses, which are embedded in the extracellular matrix (ECM). However, the mechanisms, which govern this process remain elusive. To investigate the influence of the neural ECM in synaptic remodeling by microglia, we disrupted ECM integrity by injection of chondroitinase ABC (ChABC) into the retrosplenial cortex of healthy adult mice. Using in vivo two-photon microscopy we found that ChABC treatment increased microglial branching complexity and ECM phagocytic capacity and decreased spine elimination rate under basal conditions. Moreover, ECM attenuation largely prevented synaptic remodeling following synaptic stress induced by photodamage of single synaptic elements. These changes were associated with less stable and smaller microglial contacts at the synaptic damage sites, diminished deposition of calreticulin and complement proteins C1q and C3 at synapses and impaired expression of microglial CR3 receptor. Thus, our findings provide novel insights into the function of the neural ECM in deposition of complement proteins and synaptic remodeling by microglia.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a C1q
|2 Other
650 _ 7 |a C3
|2 Other
650 _ 7 |a complement protein
|2 Other
650 _ 7 |a extracellular matrix
|2 Other
650 _ 7 |a microglia
|2 Other
650 _ 7 |a spine
|2 Other
650 _ 7 |a synapse
|2 Other
650 _ 7 |a two‐photon microscopy
|2 Other
650 _ 7 |a Complement C1q
|0 80295-33-6
|2 NLM Chemicals
650 _ 7 |a Chondroitin ABC Lyase
|0 EC 4.2.2.20
|2 NLM Chemicals
650 _ 7 |a Complement C3
|2 NLM Chemicals
650 _ 7 |a Calreticulin
|2 NLM Chemicals
650 _ 7 |a Macrophage-1 Antigen
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Microglia: metabolism
|2 MeSH
650 _ 2 |a Microglia: drug effects
|2 MeSH
650 _ 2 |a Extracellular Matrix: metabolism
|2 MeSH
650 _ 2 |a Extracellular Matrix: drug effects
|2 MeSH
650 _ 2 |a Synapses: metabolism
|2 MeSH
650 _ 2 |a Synapses: drug effects
|2 MeSH
650 _ 2 |a Synapses: physiology
|2 MeSH
650 _ 2 |a Complement C1q: metabolism
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Chondroitin ABC Lyase: pharmacology
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Neuronal Plasticity: physiology
|2 MeSH
650 _ 2 |a Neuronal Plasticity: drug effects
|2 MeSH
650 _ 2 |a Complement C3: metabolism
|2 MeSH
650 _ 2 |a Calreticulin: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Phagocytosis: physiology
|2 MeSH
650 _ 2 |a Phagocytosis: drug effects
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Macrophage-1 Antigen: metabolism
|2 MeSH
700 1 _ |a Sun, Weilun
|0 P:(DE-2719)2811509
|b 1
|u dzne
700 1 _ |a Stoyanov, Stoyan Borislavov
|0 P:(DE-2719)2809920
|b 2
700 1 _ |a Dunay, Ildiko Rita
|0 0000-0002-9900-8605
|b 3
700 1 _ |a Dityatev, Alexander
|0 P:(DE-2719)2810577
|b 4
|e Last author
773 _ _ |a 10.1002/glia.24588
|g Vol. 72, no. 10, p. 1874 - 1892
|0 PERI:(DE-600)1474828-9
|n 10
|p 1874 - 1892
|t Glia
|v 72
|y 2024
|x 0894-1491
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP1.xlsx
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP2.xlsx
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP3.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271336/files/DZNE-2024-01038.pdf
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP1.csv
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP1.ods
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP1.xls
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP2.ods
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP2.xls
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP3.doc
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP3.odt
856 4 _ |u https://pub.dzne.de/record/271336/files/DZNE-2024-01038%20SUP3.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271336/files/DZNE-2024-01038.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271336
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001455
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811509
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2809920
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810577
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GLIA : 2022
|d 2023-08-24
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-08-24
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b GLIA : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
920 1 _ |0 I:(DE-2719)1310007
|k AG Dityatev
|l Molecular Neuroplasticity
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21